Rotavirus subunit vaccines are being evaluated for use in humans. The virus-like particles (VLPs) for these vaccines are produced in insect cells coinfected with combinations of baculovirus recombinants expressing bovine RF VP2 and simian SAll VP4, VP6, or VP7 rotavirus proteins. VLPs were administered parenterally to mice and rabbits, and the immunogenicity and protective efficacy of the vaccines were evaluated. Rabbits vaccinated with VP2/4/617 or VP2/617 VLP combinations developed high levels of rotavirus-specific serum antibody and fecal IgG but not fecal IgA. The induction of fecal IgG was associated with total or partial protection from oral challenge with ALA rotavirus. Heterotypic serum and fecal neutralizing antibody was induced in mice vaccinated parenterally with G1 VP2/617 or VP2/4/617 VLPs. VLPs were highly immunogenic when administered in QS2l adjuvant, inducing serum neutralizing antibody titers comparable to those induced by SAll virus. VLPs are effective immunogens when administered parenterally and may be an effective subunit vaccine.
Rotavirus is a major cause of diarrhea in young children and animals worldwide [1] . Virtually all children are infected with the virus by the time they are 5 years old. The disease can cause a severe dehydrating diarrhea, which results in~1 million deaths in children annually, primarily in developing countries; thus, development of safe effective vaccines against rotavirus is an international priority, and efforts have focused on live oral attenuated vaccines [1] . The multivalent human-animal reassortant vaccines currently in field trials have had 70% efficacy against severe disease when tested in developed countries [2] [3] [4] .
The development of a rotavirus subunit vaccine is being investigated. Rotavirus genes encoding the rotavirus structural proteins are cloned in baculovirus, and the recombinant rotavirus proteins are coexpressed in the baculovirus expression system [5 -7] . The expressed rotavirus proteins self-assemble to form virus-like particles (VLPs). Coexpression of different combinations of structural proteins results in formation ofVLPs of different protein compositions [5] . Recent evidence that parenteral administration of live or inactivated rotavirus in rabbits results in total protection from homologous oral rotavirus challenge prompted us to evaluate this alternative route of vaccination with VLPs [8] . The immunogenicity and protective effi-cacy of parenterally administered VLPs of different compositions (VP617, VP2/617, and VP2/4/617) and in different adjuvants (AIOH and QS21) are being evaluated in mice and rabbits.
Materials and Methods and Results
Viruses and cells. The rotavirus strains used in plaque reduction, microneutralization assays, and ELISAs included ALA, Wa, S2, S1. Thomas, and SAIL All virus strains were cultivated and plaque purified in MA 104 cells [9] . Rotaviruses have a dual serotype specificity based on the two outer capsid proteins VP4 and VP7 that independently elicit neutralizing antibody (NA). VP4 serotypes are designated by P, for protease-sensitive protein. VP4 P types have been defined by serology and sequence analysis. VP4 P genotypes defined by sequence analysis are designated by a number in brackets [10] . VP4 serotypes and genotypes are not numbered identically. The serotype or genotype specificity of the viruses used in this study are ALA (P [14] , G3) (Conner ME, unpublished data), SAIl (P [2] , G3), Wa (PIA [8] , Gl), S2 (PIB [4] , G2), and S1. Thomas (P2A [6] , G4) [10] .
Production of VLPs. VLPs of differing compositions were produced by coinfection ofSf9 cells (at 0.2 or 5 pfu/cell) with different combinations of baculovirus recombinants [5] . The baculovirus recombinants used to produce the VLPs coded for bovine VP2 (RF) or VP6 (C486); simian VP6, P[2] VP4, or G3 VP7 (all SAIl); or human G 1 VP7 (8697) rotaviruses. VLPs were purified by cesium chloride density-gradient purification or by use of 40% sucrose cushions. They were characterized by biochemical analysis (for purity, protein concentration, and protein composition), electron microscopy (for integrity), ELISA (for VP7 concentration), and limulus amebocyte lysate assay (for endotoxin levels) (figure 1). The serotype of the Gland G3 VP2/6/7 and VP2/4/617 VLPs was confirmed by immunoelectron microscopy with gold-labeled monoclonal antibody probes and with a monoclonal antibodybased serotyping ELISA [5] (Crawford S, unpublished data).
Antigen and antibody assays. Virus and antigen excretion in rabbits was measured by plaque infectivity assays and ELISAs, NAs were measured by micr oneutralization assay [ 12] or by plaque reduction [9, 11, 13] . Isotype-specific and total antibody (IgA, IgM, and IgG) tite rs were measured in ELlSAs [5, 8, II , 14] .
Preparation of Rotavirus VLPs
lmmunogenicity and protection studies in mice and rabbits. Groups of 5 or 6 rotavirus-seronegative C D-I mice (C harles River, Portage, MI) were intramuscularly (im) vaccinated two times (days oand 14) with SAIl rota virus, VP617 or VP2/617 G3 VLPs (0.2 -20 jig), or buffer in either Freund ' s adjuva nt, QS21 (a purified triterpene glycoside derivati ve from the bark of Quillaj a sapon aria), or AIOH. Blood samples wer e obtained from mice before and 14 and 28 days after vaccination, and mice were exsanguinated 42 days after vaccination. Mice vacci nated with G I and G3 VP21 617 and VP2 /4/617 VLPs were vacc inated a third time at day 6 1. Fecal samples were collected from these mice at 6 1 and 75 days and assayed for rotaviru s-spec ific total antibody and IgG isotypespecific antibody .
Ten rabbits were im vac cinated tw ice with 10 or 20 jig of VP21 4/617 VLPs or buffer in either Freund 's adj uva nt or alum inum phosphate. About I month after the second vaccine, rabbit s were challenged ora lly with 10 5 pfu of ALA (G3) rabbit rotavirus. Serum and fecal samples for ant ibody assessment were collected before and after vaccination and after challenge at~2-we ek intervals. Fecal samples were collected 0-14 days after challenge and assessed for virus or ant igen excretion.
Parenteral administration of VLPs in rabbits.
We had shown previou sly that rabbits parenterally vaccinated two times with live or inactivated SAil (P [2] , G3) virus in Freund's adju vant or aluminum phosphate were totally protected (no virus or antig en excrction) against ALA (P[14] , G3) challenge [8] . Protection was asso ciated with developme nt of rota virus-specific IgG in the intestine. No rotavirus-specific IgA wa s detec ted in the intesti ne on the day of challenge, but low titers were detected after challe nge . To determ ine if a nonreplicating subunit vaccine also could induce homotypic (G3) protection from viral challenge, rabbits were vaccinated parente rally with G3 VP2 /4/617 VLP s (figure 2). All rabb its developed rota virus-specific IgG but not IgA antibody titers in the intestin e by the day of cha llenge and were totally or part ly protected from ALA rota virus challenge. Part ial protection from viral challenge was defined as significantly redu ced viral or antige n shedding compared with shedding in mock-vaccinated (PBS) controls. Rabbits im vacci nated twice with VP2/617 VLPs in QS2 1 responded similarly. Serologic antibody titers were equ ivalent to those induced by live or inactivated SA I I . The rabbits also developed rotavirus-spec ific IgG but not IgA antibo dy titers in the intestine and were partially protected from vira l challenge .
Induction ofheterotyp ic NA by G I VP2/6/ 7 and VP2/4/6/ 7 VLPs. We have previousl y show n that G3 V P2/4/617 VLPs are highly immun ogenic in mice , indu cing high Icvels ofNA [5] . In addit ion, we dem onstrated that chime ric VLPs with both a G I and a G3 VP7 displayed on the ir surface induce NA to both G I (Wa) and G3 (SA I I) viruses. In these experiments, we obtain ed preliminary data indicating that V P2/617 VLPs displaying only G I VP Figure 2 . Immunogenicity and protective efficacy of VP2/617 and VP2/4/617 VLPs in rabbits. Both formulations induced high levels of serum antibody. Rotavirus-specific IgG but not IgA was induced in intestine. Rabbits were fully or partly protected from live oral ALA rotavirus challenge. 1M, intramuscular; dpv, days after vaccination. their surface also induced NA to G3 (SAil) virus. To confirm these results and to determine if the heterotypic NAs were induced because VP4 was not present in the VLPs, mice were immunized with VP2/617 or VP2/4/617 Gl or G3 VLPs [15] . Before and 42 days after vaccination, serum samples were tested for NA to G1 (Wa), G2 (S2), G3 (SAIl), and G4 (St. Thomas) viruses. Mice vaccinated with G I VLPs, either VP2/617 or VP2/4/617, developed NA to G I and G3 viruses but not to G2 or G4 viruses. Heterotypic fecal NA to G3 virus also was detected in mice vaccinated with G I VLPs. The fecal samples have not yet been tested against G I, G2, or G4 viruses. Mice vaccinated with G3 VLPs developed intestinal homotypic NA to G3 virus.
Stability, homogeneity. and immunogenicity of VP617 and VP21 617 VLPs. Development of a stable, homogeneous, and immunogenic subunit vaccine containing the least number of coexpressed proteins in the VLPs is preferable for ease and cost of production. We have previously reported that VLPs containing bovine VP2 and simian VP6 and VP7 were more stable [5] . The stability and homogeneity of VLPs containing bovine VP6 and simian VP7 with or without bovine VP2 was assessed by electron microscopy. Following purification, the VP2/617 VLPs were more homogeneous than VP617VLPs, and more were intact (figure 3). The VP2/ 617 VLPs also maintained greater particle integrity after repeated ultracentrifugation.
The immunogenicity of VP617 and VP2/617 VLPs and SAII given parenterally was compared in CD-I mice. The immunogens were administered twice in either AIOH or QS21 adjuvant. The serum antibody responses were compared 42 days after the first vaccination by both ELISA and microneutralization assay (table  I) . Both VLP formulations in either adjuvant were immunogenic in mice. The highest antibody responses were in mice immunized with QS21, irrespective of the type of VLPs administered. Both VP617 and VP2/617 in QS21 induced antibody responses (ELISA and neutralizing) comparable to those in mice immunized with SA II in QS21. In dose-response studies with VP2/617 VLPs, the magnitude of the immune response varied with the dose of VLPs and QS21 (data not shown).
Discussion
VLPs may provide a safe and efficacious alternative or complement to live rotavirus vaccines for both human and veterinary use [16] . We have shown that VLPs administered parenterally to rabbits and mice are highly immunogenic: all formulations of VLPs induced high levels of NA and total immunoglobulin antibody in serum and intestine. In rabbits, VP2/4/617 or VP2/617 VLPs induced rotavirus-specific IgG but not IgA antibody in the intestine that was associated with protection: Vaccinated rabbits were totally or partly protected from homotypic (G3) rotavirus challenge. These data support results we obtained previously with parenterally administered live or inactivated SA 11, which induced total protection in rabbits against rotavirus challenge [8] . The lower level of protection following vaccination with VLPs correlated with titers of fecal IgG that were lower than those in rabbits vaccinated with SAil virus.
We have used a stringent measure of protective efficacy in our studies-protection from infection. In children, the protective efficacy of the live oral vaccines being field tested is based on protection from severe disease, a much less stringent measure of protective efficacy. The protective efficacy ofVLPs against clinical disease needs to be evaluated, but currently, neither the rabbit nor the mouse can be used to evaluate clinical disease . However, our data support the idea that VLPs are a safe and effective parenteral subunit vaccine that could be used alone or in conjunction with live oral or subunit oral vaccines. In our studies, the presence of rota virus -specific IgG in fecal samples correlated with protection from infection. IgA is the predominant immunoglobulin in the intestine and is expected to be the major isotype response after oral inoculation or infection [10, 17] ; however, IgG can mediate active or passive protection [8, 18] . Rotavirus-specific IgG, total antibody, and NA have been detected in fecal samples from both rabbits and mice, indicating that the presence of IgG in the intestine following parenteral vaccination is not species specific. Although we have not yet determined the source of the IgG in our studies, recent data indicate that both IgG and IgA are induced in the lamina propria of mice vaccinated parenterally with live or inactivated rhesus rotavirus [19] . The mechanism of induction of either IgG or IgA at mucosal sites following parenteral vaccination is still not understood and requires further study .
An effective vaccine in children will need to induce an immune response to multiple rotavirus serotypes [l] . For the live oral vaccines, multivalent formulations containing the four most prevalent G types (1) (2) (3) (4) are~70% efficacious against severe disease [2 -4] . However, with any vaccine (live attenu-ated or subunit), the cost of producing multivalent formulations increases as the number of components increases. The induction of NAs to both G I and G3 viruses with G I VP2/617 and VP2/4/617 VLPs indicates that it may be possible to reduce the number of G types incorporated into a subunit vaccine and that the incorporation of VP4 may not be necessary. Therefore, it may be feasible to produce VLP subunit vaccines with a limited number of types and proteins, thereby reducing production costs. Induction of heterotypic NA by the G 1 VP7 may be the result of similar amino acid sequences in the C regions of human 8697 G I and G3 rotaviruses [20] . The protective efficacy of the G 1 VLPs to homotypic and heterotypic challenge needs to be evaluated.
Although VP617 VLPs were immunogenic in mice, the relative instability and lack of homogeneity of these particles make them an unviable vaccine candidate. However, the VP2/617 VLPs are stable and homogeneous and induce high levels of NA and total antibody in both mice and rabbits. In addition, the VP2/617 VLPs induced protection in rabbits, indicating that VP4 may not be a required component of a VLP formulation.
On the basis of protection studies in rabbits and immunogenicity studies in mice and cows [16, 21] , VLPs show promise as a subunit vaccine for both humans and animals. Our results clearly indicate that alternative immunization routes (e.g., im) may be effective and warrant further investigation. Incorporation of a parenterally administered rotavirus vaccine into pediatric parenteral formulations already being given to children may be possible. Rotavirus VLPs also are being evaluated as oral immunogens, and preliminary results in mice indicate that VLPs may provide a safe and effective oral subunit vaccine.
